Regeneron Pharmaceuticals, Inc.

Sanofi Biotechnology

Allen Radin

Jennifer D Hamilton

Neil John Graham

Namita A Gandhi

Margaret Karow

Gianluca Pirozzi

Sean Stevens

Nicholas J Papadopoulos

Eric L Smith

Gang Chen

James P Fandl

Joel H Martin

Tammy T Huang

Jeanette L Fairhurst

Ashique Rafique

Kevin J Pobursky

Ana Kostic

Leda Mannent

Marius Ardeleanu

Robert B Evans

Brendan J Classon

Steven P Weinstein

Ludmila Kelly

Xia Liu

Ashish Bansal

Ariel Teper

Brad S Shumel

Vanessa Marks

Jeffrey Ming

Ross E Rocklin

Sudeep Kundu

Martine Jasson

Xiaohong Huang

Thomas Hultsch

Xing Sun

Bolanle Akinlade

Brian Swanson

Andrew J Murphy

George D Yancopoulos

Neil E Stahl

Jamie M Orengo

Scott Mellis

Joanne Papadopoulos

Meagan P O'Brien

Stefano Fiore

Stephane C Kirkesseli

Stephanie C Kirkesseli

Marcella Ruddy

Denise Calaprice

Heribert Staudinger

Hubert Van Hoogstraten

Mark Genovese

Jennifer Davidson Hamilton

Marius Ardelenau

Robert Evans

Janet Van Adelsberg

Chungpeng Fan

The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) inhibitor such as an anti-IL-4Rα antibody.

Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.

Methods for treating or preventing asthma by administering an IL-4R antagonist

The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

Methods for treating skin infection by administering an IL-4R antagonist

Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R&#x3b1;) inhibitor such as an anti-IL-4R&#x3b1; antibody.

Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)

The present invention provides methods for treating an allergy by administering one or more antibodies that bind specifically to the allergen. In certain embodiments, the antibodies useful for treating an allergen, bind specifically to the cat allergen, Fel d1. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals.

Method of treating an allergy with allergen-specific monoclonal antibodies

The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.

Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.

Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

The present invention provides methods for treating, preventing or reducing the severity of active eosinophilic esophagitis. In certain embodiments, the present invention provides methods of increasing esophageal distensibility. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4/interleukin-13 (IL-4/IL-13) pathway inhibitor such as an anti-IL-4R antibody.

Methods for treating active eosinophilic esophagitis

The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD.

Compositions for the treatment of rheumatoid arthritis and methods of using same

Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.

Methods for treating nasal polyposis by administering an IL-4R antagonist

Growing community of inventors

New York, NY, United States of America

Allen Radin